Search

The article focuses on a study conducted by researcher Gabe Sonke and colleagues which found that advanced estrogen receptor-positive, human epidermal growth factor (HER)-negative breast cancer patients who received CDK4/6 inhibitors as first-line therapy did not outlive those who received the same as second-line therapy in terms of progression-free survival (PFS) or overall survival (OS). It states that in both the first and second-line applications, CDK4/6 have demonstrated efficacy.

The article discusses research presented at the ESMO Breast Cancer annual congress, by Guilherme Nader Marta, MD, of the Institut Jules Bordet, Anderlecht, Belgium,which conducted a meta-analysis and systematic review on the association between circulating tumor DNA (ctDNA) and outcomes in early breast cancer patients. The study found that the detection of ctDNA at various time points was significantly linked to worse disease-free survival and overall survival.